Simon Cartmell is the former CEO of ApaTech Ltd, a world leader in synthetic bone graft technologies, having grown the pre-revenue business of 6 people in late 2003 to over 160 staff and $64m revenues in 2009/10. He is currently Executive Chairman of OSspray Ltd, a specialty dental company exploiting biomaterials advances to whiten, desensitise and remineralise tooth surfaces. Prior to ApaTech he worked at GlaxoWellcome in a number of U.K. and global roles, including Therapy Area Director, Infectious Diseases and Hepatitis. Simon joined Vernalis plc (formerly Vanguard Medica plc) as COO in 1998 overseeing its acquisition of Cerebrus plc in 1999. He joined the main board of Celltech plc in the role of CEO for Celltech Pharmaceuticals in mid 2000. Simon has acted as CEO/Chairman, NED and consultant for a number of Biotech companies and venture investor groups and remains an advisor to several UK and international Venture and Private Equity groups. He isa Sloan Fellow from London Business School.
Dr David Cotterell
David Cotterell is founder and MD of Apex Healthcare, the specialist pharmaceutical market research and product consulting house. He was at GlaxoSmithKline Beecham from 1990-1996. He holds a PhD and MBA.
Julie has over 20 years experience of the Pharmaceutical and Biotechnology industry. At GlaxoSmithKline for 15 years, she built up experience of early R&D strategies for early clinical Proof of concept using biomarkers and imaging methods. Latterly, her role as Head of Neuroscience and Neuropharmacology in the Psychiatry Centre of Excellence for Drug Discovery led to more than 8 new discovery programs feeding the development pipeline.
Most recently, Julie was Director and Chief Scientific Officer at BioWisdom Ltd, a global healthcare technology company. In this role, she established and led the professional services business and commercialised its safety intelligence solution.
Julie sits on several advisory boards, including the External Advisory Group for the NIHR Biomedical Research Centre in Mental Health based at Kings College, London.
Julie holds a first class honours degree in Pharmacology and a PhD in Neuroscience.
Chris has over 25 years of operational experience, has experience of both commercial and technical management and positions in blue chip companies including GlaxoSmithKline, Camelot Group and ICL.
William Bains is a respected scientist, experienced consultant and company founder.
After degrees at Oxford and Warwick and research posts in the UK and US, William worked for PA Consulting Group before joining Merlin Biosciences as Head of Technology. In 1999 he founded Amedis Pharmaceuticals and served as its founding CSO. William founded Delta-G in 2004 and sits on the Boards of MultiProSys, Karus and the SULIS fund.
Awarded the Toshiba Year of Invention prize in 1992, William is the author of numerous papers, patents and three books including the A-Z of Biotechnology.
Christopher Rumball is a New Zealand-trained medical doctor with a PhD in the developmental origins of health and disease. He has practised in New Zealand, Australia and the UK, as well as in Afghanistan in 2002-3 with Medecins sans Frontieres. While a Gates Scholar at Cambridge University in 2007-8 studying Bioscience Enterprise, he was Chief Scientific Officer for AutoTB, a startup company that won major prizes at the business plan competitions of Cambridge University and Rice University in Texas. in addition to consulting, he is also training in occupational and environmental medicine.
Dr Hakim Yadi has now joined PA Consulting. Prior to joining PA, Hakim was at IMS Health, where he worked on pricing and reimbursement assignments in therapy areas including oncology, analgesia and cardiology. Before working at IMS Health, Hakim worked for 4D-Biomedical, a specialist Translational Medicine Consultancy. Projects at 4D included the foundation of two new translational research institutes at UCL and King's College, and the structuring of a joint venture between a large NHS trust and the Leeds Institute of Genetics and Therapeutics. Hakim also worked on the formation of a biomarker and diagnostics start-up company based on University owned intellectual property. Hakim holds a BSC in Biology form the University of Bath and a PhD in Molecular Biology from Cambridge University. His PhD thesis focused on the immunological interaction between the mother and foetus during pregnancy and involved animal research, tissue culture and isolation and extensive molecular and cellular analysis. Hakim also has experience of working within the pharmaceutical industry whist on placement with UCB during his degree. At UCB Hakim worked within the molecular and cellular systems department specialising in autoimmune disease.
Miranda has 20 years’ experience of working with emerging technology businesses, and a track record of commercialising early stage life sciences technology. She provides business development services in marketing, new venture development and technology transfer. She worked in the University of Cambridge for 7 years licensing technology and founding companies with researchers, has seed capital experience from 5 years at Cambridge Research and Innovation Limited, has carried out technology audits, and implemented the UK’s annual survey of technology transfer. She is a graduate in Natural Sciences, University of Cambridge, Fellow of the Linnean Society, and Member of the US Association of University Technology Managers.